Novo Nordisk taps OpenAI for R&D

Novo Nordisk paired two messages within three weeks this spring: a broad OpenAI partnership on April 14 and a higher 2026 outlook on May 6. The Danish drugmaker said the AI tie-up will be used across drug discovery, manufacturing and commercial operations, while first-quarter results showed oral Wegovy sales of 2.26 billion Danish crowns, well ahead of analyst expectations. (money.usnews.com) The combination matters because it shows where Novo says it wants AI to work first: inside specific research and operating workflows, not as a standalone product. The company said pilot programs have already started and that full integration is planned by the end of 2026. (cnbc.com) ### Where exactly will OpenAI be used inside Novo Nordisk? (money.usnews.com) April 14 is the key date. Novo said the partnership will deploy OpenAI technology from drug discovery to manufacturing and commercial operations, with the stated aim of bringing “new and better treatment options to patients faster.” The company said the tools will be used to analyze complex datasets, identify promising drug candidates and cut the time needed to move from research to patient use. Novo also said OpenAI will help train its global workforce and raise AI literacy across departments. ### Is this just about obesity drugs? Mike Doustdar, Novo’s chief executive, tied the effort directly to obesity and diabetes when the partnership was announced. (money.usnews.com) He said millions of people living with those diseases still need treatment options and said AI would help researchers test hypotheses faster. Reuters reported the partnership comes as Novo looks for ways to regain ground in a more competitive obesity-drug market, after Eli Lilly won U.S. approval in April for its weight-loss pill Foundayo. (money.usnews.com) Novo launched oral Wegovy in the United States in January. ### What did the Wegovy pill numbers show? May 6 provided the clearest commercial data point. (cnbc.com) Novo said first-quarter oral Wegovy sales reached 2.26 billion Danish crowns, versus a Reuters-compiled analyst estimate of 1.16 billion crowns. The quarter was the first reporting period to include U.S. sales of the pill. The same results release prompted Novo to raise its 2026 guidance. (cnbc.com) The company said it now expects adjusted sales and operating profit to decline by 4% to 12% at constant exchange rates, an improvement from its earlier forecast of a 5% to 13% decline. Shares rose more than 5% in Copenhagen after the results, according to Reuters and CNBC. (money.usnews.com) ### Why are drugmakers using AI this way instead of claiming miracle discoveries? Reuters reported drugmakers are increasingly using AI to handle slower parts of development, including clinical-trial recruitment, site selection and regulatory preparation, even as executives say the technology has not yet fully delivered on the harder task of finding major new molecules. That framing helps explain Novo’s emphasis on datasets, workflow speed and productivity. (cnbc.com) OpenAI itself launched GPT-Rosalind on April 16 as a life-sciences research model aimed at evidence synthesis, hypothesis generation, experimental planning and data analysis. OpenAI said the model is designed for scientific workflows across chemistry, protein engineering and genomics, and named Amgen and Moderna among customers applying it in research and discovery. (usnews.com) ### What guardrails did Novo and OpenAI describe? Novo said the partnership includes strict data protection, governance and human oversight. Doustdar told Reuters the goal is “not replacing our scientists” but increasing productivity, and he said the arrangement was not meant to reduce the current workforce. (money.usnews.com) Sam Altman, OpenAI’s chief executive, said the collaboration would help Novo accelerate scientific discovery and run global operations more efficiently. Neither company disclosed financial terms. ### What comes next that investors and researchers can actually track? (openai.com) The next concrete milestones are already on the calendar. Novo said pilot programs are underway now across research and development, manufacturing and commercial operations, with full integration targeted by the end of 2026. Separately, the company said on May 6 that oral Wegovy is planned to launch outside the United States in the second half of 2026, pending regulatory approvals. (biospace.com) (money.usnews.com)